TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ConvaTec ( (GB:CTEC) ) just unveiled an update.
ConvaTec Group PLC has executed a share buyback program, purchasing 2,386,575 ordinary shares at prices ranging from 233.00 to 243.40 pence, as part of its $300 million buyback initiative announced earlier in August 2025. This transaction is expected to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing earnings per share and strengthening the company’s market position.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £340.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC is a global medical products and technologies company that focuses on therapies for the management of chronic conditions, with primary products in wound care, ostomy care, continence and critical care, and infusion devices.
Average Trading Volume: 7,151,469
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.8B
For an in-depth examination of CTEC stock, go to TipRanks’ Overview page.